tiprankstipranks
Advertisement
Advertisement
Boundless ceases enrollment of Phase 1/2 Potentiate trial of BBI-355, BBI-825
PremiumThe FlyBoundless ceases enrollment of Phase 1/2 Potentiate trial of BBI-355, BBI-825
3M ago
Boundless Bio Terminates Early-Stage BBI-825 Cancer Trial: What Investors Should Know
Premium
Company Announcements
Boundless Bio Terminates Early-Stage BBI-825 Cancer Trial: What Investors Should Know
3M ago
Boundless Bio Inc. Reports Q3 2025 Financial Results
Premium
Company Announcements
Boundless Bio Inc. Reports Q3 2025 Financial Results
5M ago
PremiumRatingsHold Rating on Boundless Bio Inc.: Awaiting Clinical Validation of Innovative Therapies
8M ago
Boundless Bio price target lowered to $4 from $5 at H.C. Wainwright
Premium
The Fly
Boundless Bio price target lowered to $4 from $5 at H.C. Wainwright
8M ago
Premium
Company Announcements
Boundless Bio Reports Q2 2025 Financial Results
8M ago
PremiumCompany AnnouncementsBoundless Bio Inc. Reports Q1 2025 Financial Results
11M ago
Premium
Ratings
Hold Rating Issued for Boundless Bio Inc. Amid Strategic Setbacks and Delayed Program Validations
11M ago
Boundless Bio downgraded to Market Perform from Outperform at Leerink
Premium
The Fly
Boundless Bio downgraded to Market Perform from Outperform at Leerink
11M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100